MK-8325

MK-8325 is a small molecule, tricyclic silyl compound developed as an antiviral agent targeting hepatitis C virus (HCV) infection. It acts as a potent inhibitor of the HCV nonstructural protein 5A (NS5A), demonstrating excellent pan-genotype activity in replicon assays and acceptable pharmacokinetic properties for oral administration. The compound was designed to be orally bioavailable with good absorption and distribution profiles, high protein binding, and minimal central nervous system penetration. MK-8325 was investigated primarily for its potential use in all-oral combination regimens for HCV treatment but did not reach approval[1][2][3][4][5].